Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1853 - The Research Progress in Randomized, Multicenter, Controlled Evaluation of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Gastric Cancer


Xinxin Wang


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


X. Wang, L. Chen

Author affiliations

  • General Surgery, Military General Hospital of Beijing (PLA), 100853 - Beijing/CN


Abstract 1853


There is differrence beteween the perioperative and adjuvant chemotherapy in east and west country, but there is no study to compare the effect between the perioperative and adjuvant chemotherapy based on the D2 gastrectomy in advanced gastric cancer till now. Our study wants to evaluate the efficacy and safety of S-1 and oxaliplatin as neoadjuvant chemotherapy for advanced gastric cancer.


Between September 2012 and December 2016, 420 patients with clinical stage IIA-IIIC gastric cancer were eligible for inclusion. They were randomly assigned to either the neoadjuvant chemotherapy group (n = 210) or the adjuvant chemotherapy group (n = 210). The reaction rate, effective rate, T-stage, incidences of adverse reaction, surgical R0 resection rate, CY1 rate and pCR rate in the two groups were compared.


In neoadjuvant chemotherapy group, the reaction rate, effective rate, and pCR rate were 80%, 40% and 20% respectively. The surgical R0 resection rate (80% vs 70%) were much higher in neoadjuvant chemotherapy group. There was no significant difference in incidences of adverse reaction between the two groups. However, the CY1 rate (5% vs 8%) was lower and T-stage was earlier in neoadjuvant chemotherapy group.


S-1 and oxaliplatin as neoadjuvant chemotherapy is effective for advanced gastric cancer, and there was no increase of adverse reaction.

Clinical trial identification

NCT01583361, April 4, 2012

Legal entity responsible for the study

Lin Chen


National Natural Science Foundation of China and Beijing Nova program


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.